Full Year 2023 Faron Pharmaceuticals Oy Earnings Call Transcript
Good afternoon to the Europeans, and good morning for the US people. Thank you, joining us for this annual results 2023 presentation. I'm Markku Jalkanen; I'm Faron's CEO. I'm, today, with our CFO. He's based in East Coast of US. Jim, good morning for you.
The presentation really, obviously, is looking at the '23 activities, but I want to just start with that we had a little hiccup a few weeks back. And I'm happy to say right now that that has been now corrected, and we are moving like we used to do. And Jim will report some of those activities as well. It was really unfortunate thing, and I take full responsibility of that.
So with that, you remember that we are a publicly listed company. We will be making future-looking remarks. And obviously, this is the disclaimer of those.
We have a very unique drug called bexmarilimab, a humanized antibody that has no [allergic] activity. But it has a blocking activity of receptor called CLEVER-1. I really like the name, by the way.
The CLEVER-1 antibody, what we
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
